NCT02296905 - Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Hepatic Impairment

Interventions

DRUG

ABT-493

Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.

DRUG

ABT-530

Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.

Trial Locations (4)

Site Reference ID/Investigator# 130590, Grafton

Site Reference ID/Investigator# 130591, Orlando

Site Reference ID/Investigator# 130589, Miami

Site Reference ID/Investigator# 130588, San Antonio